Every Baby in England Will Be Screened for SMA: What Parents Should Know

Babies born in England are to be screened at birth for spinal muscular atrophy (SMA), a rare but serious genetic condition — the kind of quiet public-health change that will pass most families by entirely, and transform a small number of lives completely. The screening starts in October 2026, and it matters because SMA is a condition where the difference between diagnosis at birth and diagnosis at symptoms can be the difference between a child who walks and a child who never gets the chance.

Here’s what’s changing, who it affects, and — since our readers are spread across several countries — how it compares with screening elsewhere, including the US, which is further ahead on this one.

Key takeaways

• SMA is a rare genetic condition that progressively weakens muscles; in its most severe form it affects breathing and swallowing, and untreated it is the leading genetic cause of infant death.
• Treatments now exist that can dramatically change outcomes — but they work best before symptoms appear, which is why screening at birth matters so much.
• In England, SMA screening is being added to the standard newborn heel-prick test, starting October 2026 and reaching every screening lab through 2027.
• No extra test and nothing for parents to arrange — it’s the same blood-spot test your baby would have anyway.
• US readers: American babies are already screened — SMA has been on the recommended panel since 2018, with all 50 states and DC screening since early 2024.

---

What SMA is

Spinal muscular atrophy is a genetic condition affecting the motor neurons — the nerve cells that control muscle movement. As those cells are lost, muscles weaken and waste. In its most severe and most common infant form, babies progressively lose the ability to sit, crawl and walk; eventually breathing and swallowing are affected. It’s rare — but for the families it touches, it is devastating, and speed matters enormously: every day without treatment can mean irreversible loss of motor neurons.

What has changed over the past decade is that SMA became treatable. Gene therapies and other drugs can now halt or dramatically slow the disease — with the crucial caveat that they protect the motor neurons a child still has. Treat before symptoms, and a baby’s outlook can be transformed; wait for symptoms, and some of the loss is already permanent. That’s the entire case for newborn screening in one sentence.

What’s changing in England

From October 2026, screening for SMA will begin across England as part of a national evaluation programme — rolled out through the newborn blood spot test (the heel prick) that babies already have in their first days. There is nothing new for parents to do or arrange: the same small blood sample, now checked for one more thing.

The rollout is phased: the first laboratories begin testing in October 2026 — three months ahead of the original schedule — with the remaining screening labs joining from October 2027, so that every newborn in England is covered. Scotland already runs a similar programme. Alongside the rollout, a £4.1 million evaluation led by University of Oxford researchers will gather real-world evidence to inform the UK National Screening Committee’s decision on making SMA screening a permanent part of the panel.

It’s worth pausing on how this happened: years of campaigning by families affected by SMA, alongside charities including SMA UK and Muscular Dystrophy UK. Campaigner Jesy Nelson, whose family has been directly affected, called the announcement “a day of hope” — “whilst it can’t change the future of our children, it marks the beginning of a brighter future for future SMA families.” Screening programmes rarely arrive on their own; someone’s hard years are usually underneath them.

The international picture

For US readers: this is one area where American babies are already covered. SMA was added to the federal Recommended Uniform Screening Panel in 2018, and as of February 2024 all 50 states and Washington, DC screen every newborn for SMA as standard. If your baby was born in the US in the last couple of years, this test has almost certainly already been done — inside the same routine heel-prick most parents barely register.

Elsewhere: newborn SMA screening is spreading steadily — much of Europe, Australia and other countries now screen or are phasing it in. If you’re unsure whether your country includes SMA in its newborn panel, your midwife, paediatrician or child health service can tell you.

What this means in practice

For the overwhelming majority of families, nothing: the test comes back clear and you never think about it again. For the few dozen families a year in England whose babies screen positive, it means specialist referral and the chance to start treatment in the window when it helps most — instead of the months-long “diagnostic odyssey” families previously endured while symptoms slowly declared themselves.

If a screening result ever does come back positive for your baby, the advice from every SMA charity is the same: it will move fast, that’s by design, and the specialist teams you’re referred to are good at this. And if you have concerns about a baby’s movement or muscle tone at any age — screening or no screening — raise them with your health visitor, GP or paediatrician; screening catches the genetic condition, but parents remain the best early-warning system for everything else.

---

Sources: GOV.UK — Every baby in England to get life-saving genetic test from birth (August 2026); Cure SMA — Newborn Screening for SMA; Muscular Dystrophy Association — All 50 States and DC Implement SMA Newborn Screening (2024).